Piqray is owned by Novartis.
Piqray contains Alpelisib.
Piqray has a total of 2 drug patents out of which 0 drug patents have expired.
Piqray was authorised for market use on 24 May, 2019.
Piqray is available in tablet;oral dosage forms.
Piqray can be used as in combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer.
Drug patent challenges can be filed against Piqray from May, 2023.
The generics of Piqray are possible to be released after 28 September, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(6 years from now) | |
US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 24, 2024 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic